{"entity":{"id":"tepotinib","kind":"drug","name":"Tepotinib","aka":["MSC2156119","EMD 1214063"],"tldr":"Tepotinib is a once-daily targeted pill for lung cancers driven by a MET exon 14 skipping mutation, and the MET inhibitor NICE funds in England.","summary":"Tepotinib is an oral MET inhibitor for advanced non-small cell lung cancer with MET exon 14 skipping alterations, which can be detected in tumour tissue or in circulating tumour DNA. The VISION trial showed durable responses in about half of patients whether or not they had been treated before. Japan approved it first in 2020, the FDA in 2021 and the EU in 2022. NICE recommended it in 2022 within its licence with a commercial arrangement. Peripheral oedema is the main side effect.","status":"approved","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Tepotinib","links":[{"label":"VISION (NEJM 2020)","url":"https://doi.org/10.1056/NEJMoa2004407"},{"label":"Label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=tepotinib"}],"tags":["gap-fill"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["met"],"drugs":["capmatinib"],"companies":["merck-kgaa"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"brand":"Tepmetko","modality":"Small-molecule MET tyrosine kinase inhibitor","mechanism":"A highly selective, once-daily MET kinase inhibitor that blocks signalling from MET receptors kept active by exon 14 skipping mutations.","approvals":[{"region":"US","year":2021,"indication":"Metastatic NSCLC with MET exon 14 skipping alterations"},{"region":"EU","year":2022,"indication":"Advanced NSCLC with MET exon 14 skipping alterations after immunotherapy or platinum chemotherapy"},{"region":"JP","year":2020,"indication":"Unresectable advanced or recurrent NSCLC with MET exon 14 skipping"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tepotinib/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"drug":[{"id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/"}],"company":[{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"}]}}